Three companies move very nearly the entire supply of prescription drugs in the United States. They are not household names, they earn razor-thin margins on each item, and they are among the most important businesses in healthcare. The drug distributor stocks in this link prove a useful investing lesson: a thin margin on an enormous, essential volume can be a stronger position than a fat margin on something easily replaced.
Part 7 of 8
Distributors & PBMs
4 Jun 2026The middlemen: the plumbing between drug, dollar, and patient
The hidden middlemen of US healthcare — McKesson, Cencora, Cardinal Health — plus how PBMs and the Walgreens take-private reshaped the chain.
Key Takeaways
- 1This article covers key developments in the crypto market
- 2Always verify claims with official FCA and regulatory sources
- 3Past performance does not guarantee future results
- 4Consider speaking to a qualified financial adviser before acting
- 5TradeRadarNews provides information only — not financial advice
Between the drugmaker and the patient sits a layer of distributors and pharmacy-benefit managers most people never see — high-volume, thin-margin, and quietly powerful.
Where this sits in the chain
The Middlemen are the plumbing connecting the drugmakers to the providers and patients who use their products — while the money flows back through The Payers. For the full map, see The System.
What this link is
- The drug distributor (the "big three"). Distributors buy drugs from manufacturers and deliver them to pharmacies and hospitals — handling logistics, storage, and credit for the whole system. Three firms dominate.
- The pharmacy-benefit manager (PBM). A PBM sits between insurers, drugmakers, and pharmacies, deciding which drugs an insurance plan covers (the formulary) and negotiating rebates from manufacturers in return for favourable placement. PBMs are powerful, profitable, and controversial — critics argue their rebate economics inflate list prices.
- The twist: the largest PBMs are not independent. They are owned by the giants in the previous link.
The companies
McKesson (MCK)
What they do: the largest US drug distributor, moving vast volumes of medicines to pharmacies and providers. The numbers: [refresh: latest quarter revenue; note the very low margin on huge revenue]. The edge: enormous scale and logistics infrastructure that would be extraordinarily hard to rebuild — a quiet but real moat. The risk: the legacy of opioid-distribution lawsuits (large multi-year settlements) and the permanent squeeze of thin margins.
Cencora (COR)
What they do: a leading distributor (formerly AmerisourceBergen), with particular strength in specialty and complex drugs. The numbers: [refresh: latest quarter; specialty mix]. The edge: depth in high-value specialty distribution, a growing slice of drug spending. The risk: heavy reliance on a small number of very large customers, plus the same litigation legacy as its peers.
Cardinal Health (CAH)
What they do: distributes drugs and also makes and sells medical products. The numbers: [refresh: latest quarter; segment split]. The edge: the distribution-plus-products combination, with a turnaround in its medical segment. The risk: thin margins, execution questions in the medical-products unit, and shared opioid-litigation exposure.
The PBMs — owned, not standalone
The three largest pharmacy-benefit managers are CVS Caremark (part of CVS Health, CVS), Express Scripts / Evernorth (part of Cigna), and Optum Rx (part of UnitedHealth). This is the chain's biggest hidden-integration story: the companies that pay for drugs also run the gatekeepers that decide which drugs are covered. It is why PBM reform is such a live political issue — and why this link cannot be understood without the payers.
A former giant that left the market. Walgreens Boots Alliance was, for decades, a listed pharmacy giant. In August 2025 it was taken private by Sycamore Partners, delisted, and split into five standalone private companies. It is no longer an S&P 500 stock — a reminder that even the largest names can exit public markets. CVS Health (CVS) is now the surviving listed hybrid of retail pharmacy, insurer, and PBM.
The bull and bear case
The bull case: the distributors are an entrenched oligopoly handling defensive, must-have volumes; the work is unglamorous, essential, and very hard to displace.
The bear case: margins are structurally thin, the opioid-litigation tail still lingers, and the PBM model faces serious political and regulatory scrutiny that could reshape how the whole link earns its money.
What feeds it, what it feeds
The Middlemen are fed by the drugmakers whose products they move, and they connect to The Payers who own the PBMs and fund the bill. That completes the chain, from lab bench to bill. The regulatory and pricing pressures bearing down on this link are gathered in The Forces — the final piece. Back to the map: The System.
This article is for information only and is not investment advice or a recommendation to buy or sell any security. [Publication] is not a licensed financial adviser. Figures are accurate as of June 2026 and will change. Markets carry risk, including loss of capital. Rules, taxes, and available products differ by country — do your own research and consider a locally regulated professional.
Risk Warning: Trading and investing carries significant risk. Your investments can fall as well as rise. CFDs carry high risk of rapid loss due to leverage. Cryptocurrency is not FCA-regulated and not covered by FSCS. This is information only, not financial advice. Seek independent advice before investing.
Written by
TradeRadarNews Team
Editorial Team
Our editorial team covers markets, fintech, and regulatory developments across the UK and globally.